Sandoz Files Application In Japan For G-CSF Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Sandoz has filed for approval in Japan of a biosimilar recombinant human G-CSF for the treatment of neutropenia, a side effect of chemotherapy.